What NeuImmune does

NeuImmune, Inc. is an early-stage biotechnology company developing precision glycoengineered biologics for orphan diseases and infectious disease applications. The company was founded in 2020 by scientists from the University of Maryland, University of California San Diego, and the Technical University of Denmark, and is headquartered in Sykesville, Maryland with 11-50 employees. Its core technology consists of two proprietary platforms: the geCHO BioDesign Platform, a comprehensive panel of glycoengineered Chinese Hamster Ovary (CHO) cells capable of uniformly producing diverse human-like glycoforms of therapeutic proteins and vaccine antigens, combined with AI tools for optimal glycoform identification and bioproduction optimization; and ICAM-1 Targeting Technology, which fuses geCHO proteins with ICAM-1-binding peptides to enable enhanced cellular delivery and enzymatic activity, including CNS and visceral organ access via intravenous dosing for lysosomal storage disorders. The company licenses the geCHO platform from a program developed with over $50M in support from the Novo Nordisk Foundation at the Technical University of Denmark.

NeuImmune operates a platform-plus-pipeline business model, applying its dual technology stack to advance preclinical pipeline programs including ICAM-1-ASM for Niemann-Pick Disease Types A and A/B (addressing neurological involvement not covered by existing enzyme replacement therapy Olipudase alfa) and recombinant Antithrombin (rhAT) for antithrombin deficiency. The company is pre-commercial with no disclosed product revenue; it monetizes through research grants, strategic government contracts (notably a $22.2M BARDA BioMaP-Consortium award for filovirus antibody biomanufacturing in partnership with Ginkgo Bioworks, announced November 2025), and a strategic licensing/government-funded collaboration model. Its customer segments are vertical-organized: primary focus on orphan disease patients with lysosomal storage disorders (particularly Niemann-Pick disease), and a secondary infectious disease segment targeting filoviral hemorrhagic fevers including Ebola and Sudan Virus. Pricing is not publicly disclosed as the company remains in preclinical development.

The company is led by Executive Chairman Thomas Fuerst, PhD (former Scientific Founder at MedImmune, Director of Biodefense at BARDA, and Director at DARPA), CTO Nathan Lewis, PhD (CHO genome sequencing pioneer and systems biology/AI expert), VP of gCHO Cell Manufacturing Bjorn Voldborg, MSc (former head of the NNF-funded National Biologics Facility at DTU), and Board Advisor Armand Girard, MBA (former CBO at GlycoMimetics and VP at Shire Pharmaceuticals). NeuImmune relies on scientific publications, press releases, and institutional partnerships (NIH, BARDA, Novo Nordisk Foundation, Ginkgo Bioworks, Kemp Proteins) for visibility and demand generation rather than commercial sales infrastructure.

Name

NeuImmune

Legal name

NeuImmune, Inc.

Website

https://neuimmune.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

NeuImmune is an early-stage biotechnology company developing precision glycoengineered biologics using its proprietary geCHO BioDesign platform and ICAM-1 targeting technology, advancing preclinical pipeline programs for orphan diseases including Niemann-Pick disease and antithrombin deficiency.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Research and Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Glycoengineered biologics
• CHO cell engineering
• ICAM-1 targeted delivery
• Lysosomal storage disorders
• Biopharmaceutical pipeline development

Headquarters

HQ city

Sykesville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Distribution channels1 record

Marketing channels3 records

Core offering

NeuImmune develops a glycoengineering and targeted-delivery platform for producing precision biologics, including the geCHO BioDesign Platform and ICAM-1 Targeting Technology. It also advances preclinical therapeutic programs, including ICAM-1-ASM for Niemann-Pick disease and recombinant antithrombin for antithrombin deficiency.

Product overview

NeuImmune is an early-stage biotechnology company offering a precision glycoengineering platform for biologics development. The core offering consists of the geCHO BioDesign Platform (glycoengineered CHO cell lines for producing human-like glycoforms) combined with ICAM-1 Targeting Technology (enhanced drug delivery via ICAM-1 receptor targeting). The company applies these platforms to develop pipeline candidates including ICAM-1-ASM for Niemann Pick Disease and recombinant Antithrombin for antithrombin deficiency, both enzyme replacement therapies for lysosomal storage disorders and rare diseases. NeuImmune operates as a platform-plus-pipeline model, licensing its technology while advancing proprietary therapeutic programs.

Differentiator

Problem solved

Functional benefit

Brands

• geCHO BioDesign Platform: Comprehensive panel of glycoengineered CHO cells capable of uniformly producing diverse human-like glycoforms of therapeutic proteins and vaccine antigens, combined with AI platforms for optimal glycoform identification and bioproduction optimization.
• ICAM-1 Targeting Technology

Products and services

• geCHO BioDesign Platform A comprehensive panel of glycoengineered Chinese Hamster Ovary cells that uniformly produces diverse human-like glycoforms of therapeutic proteins and vaccine antigens, combined with AI platforms to identify optimal glycoforms for functional activity and bioproduction optimization.
• ICAM-1 Targeting Technology A targeting technology that combines geCHO proteins with ICAM-1-binding peptides to enhance cellular delivery and enzymatic activity, enabling central nervous system and visceral-organ access through intravenous dosing for lysosomal storage disorders.
• ICAM-1-ASM (Niemann Pick Disease) A preclinical program targeting acid sphingomyelinase for Niemann-Pick disease types A and A/B. It uses an ICAM-1-ASM fusion protein to enable central nervous system delivery across the blood-brain barrier and address neurological involvement not covered by existing enzyme replacement therapy.
• Recombinant Antithrombin (rhAT) A preclinical program developing fully humanized recombinant antithrombin using the geCHO platform as an alternative to plasma-derived therapy, which carries blood-borne pathogen-transmission risks and has a short half-life.

Quantifiable outcome

• ICAM-1 targeting reduced brain storage of sphingomyelin substrate and secondary cholesterol in ASM knockout mice in preclinical studies
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Ginkgo BioworkscoreStrategic or Co-development Partner · 4 November 2025Strategic collaboration to develop innovations strengthening domestic biomanufacturing of monoclonal antibodies targeting filoviruses such as Ebola and Sudan Viruses. NeuImmune contributes its geCHO BioDesign platform while Ginkgo provides cell-programming foundry, automation, and AI infrastructure. Project funded through BARDA's BioMaP-Consortium.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Emerging players

• Avidity Biosciences: Avidity uses antibody-based targeted delivery to enable oligonucleotide therapeutics for serious genetic diseases. The company is comparable as an emerging antibody-delivery platform focused on rare disease, though its chemistry and target tissues differ from NeuImmune's protein therapeutics.
• Passage Bio: Passage Bio develops genetic medicines for rare monogenic CNS disorders, with an emphasis on neurological disease and delivery to the brain. It is comparable in target indications and CNS focus, although Passage Bio uses gene therapy rather than glycoengineered proteins.
• Denali Therapeutics: Denali develops precision medicines for neurodegenerative and rare diseases and invests in blood-brain barrier shuttle technology for antibodies and enzyme-replacement programs. It is relevant as a biologics-delivery peer focused on improving CNS exposure, although its delivery modality differs from ICAM-1 targeting.
• Sangamo Therapeutics: Sangamo develops engineered cell and gene therapies with programs in rare genetic diseases. It is a relevant platform-biotech comparator because it combines advanced biological engineering with specialty therapeutic development, although it does not share NeuImmune's glycoengineering focus.
• Alcyone Therapeutics: Alcyone Therapeutics develops precision genetic medicines and CNS-delivery technologies for neurological and other rare diseases. Its platform-plus-pipeline approach and focus on controlled brain delivery are comparable to NeuImmune's ICAM-1 targeting strategy.

Others

• Ginkgo Bioworks: Ginkgo provides cell programming, automation, AI, and biomanufacturing infrastructure rather than competing therapeutic products. It is comparable to NeuImmune as a biological engineering and manufacturing platform, and it is also a named strategic collaborator.

Broad incumbents

• BioMarin Pharmaceutical: BioMarin is an established rare-disease biopharmaceutical company with commercial experience in enzyme-replacement and other specialty biologics, including lysosomal disorders. It provides a relevant commercial and development benchmark for NeuImmune's orphan-disease pipeline.

Direct peers

• JCR Pharmaceuticals: JCR Pharmaceuticals develops recombinant biopharmaceuticals for rare diseases and has a proprietary J-Brain Cargo technology for delivering biologics across the blood-brain barrier. Its combination of biologics manufacturing and targeted CNS delivery is closely comparable to NeuImmune's geCHO and ICAM-1 platforms.
• Selexis: Selexis provides CHO cell-line development and recombinant-protein manufacturing technologies for biologics producers. Its cell-engineering platform is directly comparable to NeuImmune's use of glycoengineered CHO cells to optimize biologic production.
• Glycotope: Glycotope develops human cell-line and glycoengineering platforms for producing optimized therapeutic antibodies and other glycoproteins. Its glycoengineering capabilities and platform-based business model make it a close technology peer to NeuImmune's geCHO system.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/neuimmune

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuImmune